Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
NCT03544060 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2021-09-16
Summary
The purpose of this program is to provide expanded access to volanesorsen for up to 100 Patients with Familial Chylomicronemia Syndrome (FCS).
Conditions
- Familial Chylomicronemia
Interventions
- DRUG
-
Volanesorsen
Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
Sponsors & Collaborators
-
CaligorRx, Inc.
collaborator UNKNOWN -
Akcea Therapeutics
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations
NCT02934698 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
NCT03601637 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
NCT03068312 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
NCT00953706 ·Status: TERMINATED ·Phase: PHASE2
-
Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
NCT04235140 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation
NCT02565914 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT03460990 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
NCT02070744 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
NCT03625466 ·Status: COMPLETED ·Phase: PHASE2
-
Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis
NCT03278314 ·Status: APPROVED_FOR_MARKETING
-
A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
NCT03525548 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
NCT00909532 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
NCT01931839 ·Status: COMPLETED ·Phase: PHASE3
-
VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)
NCT04058210 ·Status: APPROVED_FOR_MARKETING
-
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT03029455 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
NCT01685801 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
NCT03447262 ·Status: TERMINATED ·Phase: PHASE3
-
Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
NCT02532764 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
NCT01225211 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients
NCT02722057 ·Status: COMPLETED
-
Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF
NCT06468527 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis
NCT00073463 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.
NCT04623879 ·Status: COMPLETED
-
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
NCT02797132 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
NCT02589236 ·Status: COMPLETED ·Phase: PHASE2